June 30, 2023 – Great News! The third paper from the Benzodiazepine Survey of 2018-2019 — which focuses on benzodiazepine-induced neurological dysfunction (BIND) — was the subject of an article yesterday in Psychology Today.
In the article titled "Benzodiazepines Linked to Long-Term Neurological Dysfunction, " author Christopher Lane, Ph.D. reviewed the the paper and highlighted some of its key findings. The third paper was titled "Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey," and was published in the open access journal PLOS ONE on June 29, 2023.
Our team has been working on this survey for four years now, and we now have three scientific publications published reporting on the direct experiences that patients have endured from exposure to benzodiazepines. Previous studies on this survey include, “Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey.” and “Enduring neurological sequelae of benzodiazepine use: and Internet survey., both published in the journal Therapeutic Advances in Psychopharmacology.
Our research team includes Alexis Ritvo, MD, MPH (University of Colorado Anschutz Medical Center), D E Foster (Benzodiazepine Action Work Group / Easing Anxiety), Christy Huff, MD (Benzodiazepine Information Coalition), Bernard Silvernail, MS (The Alliance for Benzodiazepine Best Practices), and Peter R. Martin, MD, MSc and A. J. Reid Finlayson, MD from Vanderbilt University.
Special thanks to Dr. Jane Macoubrie for conceptualizing this survey, to Jo Ann LeQuang for her amazing writing services on the paper, and to the Alliance for Benzodiazepine Best Practices for their unyielding support of this research. But most of all, I want to thank the individuals who struggle with BIND each and every day, and who took the time to share their stories and experiences with the survey. Thank you!